Brief: Soleno Therapeutics Q4 EPS USD 0.8
25/02/2026 21:01
Feb 25 (Reuters) - Soleno Therapeutics Q4 basic EPS USD 0.82. Q4 operating income USD 39.577 million Q4 operating expenses USD 52.153 million Q4 net income USD 43.358 million
Recent news on Soleno Therapeutics
See all newsNASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: EMA's CHMP Recommends Granting A Marketing Authorisation For Cenrifki (Tolebrutinib)